Abstract
Matrix metalloproteinases (MMPs) are the zinc-dependent endopeptidases that mediate the degradation of the extracellular matrix (ECM) constituents and basement membrane to facilitate tumorigenic invasion. Reducing cell adhesion, stimulating neoangiogenesis, and inhibiting cancer cell apoptosis are the other prominent MMP-mediated subsidiary mechanisms facilitating the oncogenic processes. Further, abundant experimental and clinical evidences regarding the differential overexpression of several MMPs in various solid as well as nonsolid tumors have rendered them as potential immunotherapeutic targets against diverse cancer types. Currently, MMP-based cancer immunotherapy principally relies upon inhibition of MMP activity by either synthetic MMP inhibitors (MMPIs) or MMP-based cancer vaccines. Although the MMPIs generated considerable interest during the 1990s, they failed to sustain the expectation due to considerable side effects. Despite the initial embarrassment, now the pursuit is directed towards the development of selective and more potent inhibitors rather than the earlier broad-spectrum MMPIs along with customization of targeted delivery systems for these compounds. Alternatively, MMP-based DNA vaccines, particularly the xenogeneic vaccine strategy, have gained significant consideration in recent times due to promising response against some cancer types in preclinical models. So, this chapter elaborates about the biological functions of different MMPs in cancer, their inhibitors, and MMP-based vaccines for cancer immunotherapy as well as the challenges and future prospects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, Thor SP (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57(11):1735–1743. https://doi.org/10.1007/s00262-008-0480-y
Baciu PC, Suleiman EA, Deryugina EI, Strongin AY (2003) Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res 291(1):167–175. https://doi.org/10.1016/s0014-4827(03)00387-2
Bai Y, Yang H, Zhang G, Hu L, Lei Y, Qin Y, Yang Y, Wang Q, Li R, Mao Q (2017) Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol Med Rep 15(2):885–889. https://doi.org/10.3892/mmr.2016.6051
Benaud C, Dickson RB, Thompson EW (1998) Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50(2):97–116. https://doi.org/10.1023/a:1006061115909
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744. https://doi.org/10.1038/35036374
Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 24(21):4582–4585. https://doi.org/10.1016/j.vaccine.2005.08.027
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385(6618):729–733. https://doi.org/10.1038/385729a0
Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, Filetti LC, Mobashery S, Cher ML, Fridman R (2006) Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 118(11):2721–2726. https://doi.org/10.1002/ijc.21645
Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35(2):161–204. https://doi.org/10.1016/s0165-0173(01)00045-5
Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang XM, Liu ZG (2016) Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration. Cell Res 26(8):886–900. https://doi.org/10.1038/cr.2016.87
Chandler S, Cossins J, Lury J, Wells G (1996) Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun 228(2):421–429. https://doi.org/10.1006/bbrc.1996.1677
Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. (2007) A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 13(7):2091–2099. https://doi.org/10.1158/1078-0432.CCR-06-1586
Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS malignancy consortium study. J Clin Oncol 24(9):1389–1394. https://doi.org/10.1200/JCO.2005.04.2614
Dong Z, Kumar R, Yang X, Fidler IJ (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88(6):801–810. https://doi.org/10.1016/s0092-8674(00)81926-1
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174. https://doi.org/10.1038/nrc745
Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28(6):620–625. https://doi.org/10.1016/s0093-7754(01)90035-1
Fang H, Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73(16):4965–4977. https://doi.org/10.1158/0008-5472.CAN-13-0661
Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 97(8):3884–3889. https://doi.org/10.1073/pnas.97.8.3884
Feltquate DM, Heaney S, Webster RG, Robinson HL (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158(5):2278–2284
Fields GB (2019) Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases. Front Immunol 10:1278. https://doi.org/10.3389/fimmu.2019.01278
Fischer T, Riedl R (2019) Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules 24(12):2265. https://doi.org/10.3390/molecules24122265
Fisher JF, Mobashery S (2006 Mar) Recent advances in MMP inhibitor design. Cancer Metastasis Rev 25(1):115–136. https://doi.org/10.1007/s10555-006-7894-9
Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167(12):7150–7156. https://doi.org/10.4049/jimmunol.167.12.7150
Fowlkes JL, Enghild JJ, Suzuki K, Nagase H (1994) Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 269(41):25742–25746
Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123(Pt 24):4195–4200. https://doi.org/10.1242/jcs.023820
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90(24):11478–11482. https://doi.org/10.1073/pnas.90.24.11478
Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, Scanziani E, Casazza AM, Taraboletti G, Giavazzi R (1999) BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5(11):3603–3607
Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27. https://doi.org/10.1111/j.1742-4658.2010.07919.x
Giarelli E (2007) Cancer vaccines: a new frontier in prevention and treatment. Oncology (Williston Park) 21(11):11–17. Discussion 18
Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD (2011) Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72(12):1631–1638. https://doi.org/10.2460/ajvr.72.12.1631
Gweon EJ, Kim SJ (2014) Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep 32(1):71–78. https://doi.org/10.3892/or.2014.3192
Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A (1999) Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6):589–596. https://doi.org/10.1016/s0264-410x(98)00238-2
Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19(17–19):2576–2582. https://doi.org/10.1016/s0264-410x(00)00485-0
Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM (2000) Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105(2):143–150. https://doi.org/10.1172/JCI7091
Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267(36):26031–26037
Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326:1216–1219
Illman SA, Lehti K, Keski-Oja J, Lohi J (2006) Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18):3856–3865. https://doi.org/10.1242/jcs.03157
Itoh K, Yamada A, Mine T, Noguchi M (2009) Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 39(2):73–80. https://doi.org/10.1093/jjco/hyn132
Jablonska-Trypuc A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31(sup1):177–183. https://doi.org/10.3109/14756366.2016.1161620
Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R (2009) Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 61(2):198–223. https://doi.org/10.1124/pr.109.001289
Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409):594–599. https://doi.org/10.1016/S0140-6736(04)15590-6
Karim BO, Huso DL (2013) Mouse models for colorectal cancer. Am J Cancer Res 3(3):240–250
Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, Bishayee A, Ahn KS (2017) The role of resveratrol in cancer therapy. Int J Mol Sci 18(12):2589. https://doi.org/10.3390/ijms18122589
Kochenderfer JN, Gress RE (2007) A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 232(9):1130–1141. https://doi.org/10.3181/0702-MR-42
Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V (2000) Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148(3):615–624. https://doi.org/10.1083/jcb.148.3.615
Kruger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R (2005) Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65(9):3523–3526. https://doi.org/10.1158/0008-5472.CAN-04-3570
Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST (1998) Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55(1):29–42. https://doi.org/10.1006/mvre.1997.2056
Laronha H, Caldeira J (2020) Structure and function of human matrix metalloproteinases. Cell 9(5):1076. https://doi.org/10.3390/cells9051076
Levin M, Udi Y, Solomonov I, Sagi I (2017) Next generation matrix metalloproteinase inhibitors–novel strategies bring new prospects. Biochim Biophys Acta, Mol Cell Res 1864(11 Pt A):1927–1939. https://doi.org/10.1016/j.bbamcr.2017.06.009. Epub 2017 Jun 19
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139(7):1861–1872. https://doi.org/10.1083/jcb.139.7.1861
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395–406. https://doi.org/10.1083/jcb.201102147
Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272(41):25706–25712. https://doi.org/10.1074/jbc.272.41.25706
Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ (2011) Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 25(1):94–99. https://doi.org/10.1111/j.1939-1676.2010.0627.x
Maquoi E, Assent D, Detilleux J, Pequeux C, Foidart JM, Noël A (2012) MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. Oncogene 31(4):480–493. https://doi.org/10.1038/onc.2011.249
Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P (2005) ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A 102(26):9182–9187. https://doi.org/10.1073/pnas.0500918102
Meisel JE, Chang M (2017) Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease. Biochim Biophys Acta, Mol Cell Res 1864(11 Pt A):2001–2014. https://doi.org/10.1016/j.bbamcr.2017.04.011
Meyer E, Vollmer JY, Bovey R, Stamenkovic I (2005) Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 65(10):4261–4272. https://doi.org/10.1158/0008-5472.CAN-04-2908
Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573. https://doi.org/10.1016/j.cardiores.2005.12.002
Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA (2001) Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 61(23):8480–8485
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114(Pt 1):111–118
Noel A, Jost M, Maquoi E (2008) Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 19(1):52–60. https://doi.org/10.1016/j.semcdb.2007.05.011
Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, Fang L, Lee SW (2004) HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64(15):5283–5290. https://doi.org/10.1158/0008-5472.CAN-04-0925
O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA (1999) Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274(41):29568–29571. https://doi.org/10.1074/jbc.274.41.29568
Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J (2000) Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11(2):97–133
Pertmer TM, Roberts TR, Haynes JR (1996) Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 70(9):6119–6125. https://doi.org/10.1128/JVI.70.9.6119-6125.1996
Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L (2009) MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 15(12):4104–4113. https://doi.org/10.1158/1078-0432.CCR-08-3226
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development. Science 282(5392):1281–1284. https://doi.org/10.1126/science.282.5392.1281
Potebnya GP, Symchych TV, Lisovenko GS (2010) Xenogeneic cancer vaccines. Exp Oncol 32(2):61–65
Radisky DC, Levy DD, Littlepage LE (2005) Rac1b and reactive oxygen species mediate MMP- 3-induced EMT and genomic instability. Nature 436:123–127
Rangarajan A, Weinberg RA (2003) Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3(12):952–959. https://doi.org/10.1038/nrc1235
Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, Chestukhina GG, Smith JW, Deryugina EI, Strongin AY (2002) An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem 277(9):7377–7385. https://doi.org/10.1074/jbc.M109580200
Roth GA, Mensah GA, Johnson CO et al (2021) GBD-NHLBI-JACC global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 77(15):1958–1959. https://doi.org/10.1016/j.jacc.2020.11.010
Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297. https://doi.org/10.1200/JCO.2009.23.5556
Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY (2004) The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem 279(6):4260–4268. https://doi.org/10.1074/jbc.M311569200
Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164(5):769–779. https://doi.org/10.1083/jcb.200307137
Sainio A, Jarvelainen H (2014) Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy. Mol Cell Ther 2:14. https://doi.org/10.1186/2052-8426-2-14
Scappaticci FA, Contreras A, Boswell CA, Lewis JS, Nolan G (2003) Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine 21(19–20):2667–2677. https://doi.org/10.1016/s0264-410x(02)00693-x
Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli M, Sotgia F, Lisanti MP, Naccarato AG (2018) Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: A clinical pilot study. Front Oncol 8:452. https://doi.org/10.3389/fonc.2018.00452
Schafer B, Marg B, Gschwind A, Ullrich A (2004) Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279(46):47929–47938. https://doi.org/10.1074/jbc.M400129200
Schulte M, Reiss K, Lettau M, Maretzky T, Ludwig A, Hartmann D, de Strooper B, Janssen O, Saftig P (2007) ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 14(5):1040–1049. https://doi.org/10.1038/sj.cdd.4402101
Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV (2007) Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother 61(2–3):125–130. https://doi.org/10.1016/j.biopha.2006.09.016
Seledtsov VI, Shishkov AA, Surovtseva MA, Samarin DM, Seledtsova GV, Niza NA, Seledtsov DV (2006) Xenovaccinotherapy for melanoma. Eur J Dermatol 16(6):655–661
Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J (2006) Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 169(4):1390–1401. https://doi.org/10.2353/ajpath.2006.060005
Slingluff CL Jr, Speiser DE (2005) Progress and controversies in developing cancer vaccines. J Transl Med 3(1):18. https://doi.org/10.1186/1479-5876-3-18
Smith TM Jr, Tharakan A, Martin RK (2020) Targeting ADAM10 in cancer and autoimmunity. Front Immunol 11:499. https://doi.org/10.3389/fimmu.2020.00499
Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14(12):1357–1362. https://doi.org/10.1038/nm.1885
Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: eastern cooperative oncology group trial E2196. J ClinOncol 22(23):4683–4690. https://doi.org/10.1200/JCO.2004.08.054. Erratum in: J ClinOncol. 2005 Jan 1;23(1):248
Sprent J, Surh CD (2001) Generation and maintenance of memory T cells. Curr Opin Immunol 13(2):248–254. https://doi.org/10.1016/s0952-7915(00)00211-9
Srinivasan R, Wolchok JD (2004) Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2(1):12. https://doi.org/10.1186/1479-5876-2-12
Su CW, Lin CW, Yang WE, Yang SF (2019) TIMP-3 as a therapeutic target for cancer. Ther Adv Med Oncol 11:1758835919864247. https://doi.org/10.1177/1758835919864247
Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B (2003) Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 63(3):600–607
Sunil Kumar BV, Aswani Kumar K, Padmanath K et al (2013) Development of recombinant matrix metalloproteinase-11 based sandwich ELISA for the diagnosis of canine mammary tumor. Proc Natl Acad Sci, India, Sect B Biol Sci 83:181–185. https://doi.org/10.1007/s40011-012-0127-9
Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M (1997) Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272(50):31730–31737. https://doi.org/10.1074/jbc.272.50.31730
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. https://doi.org/10.1038/nrc822
Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL (1995) Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136(8):3527–3533. https://doi.org/10.1210/endo.136.8.7543045
Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK, Sharma U, Jain A, Aggarwal V, Bishayee A (2019) Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol 10:1336. https://doi.org/10.3389/fphar.2019.01336
Unemori EN, Ferrara N, Bauer EA, Amento EP (1992) Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153(3):557–562. https://doi.org/10.1002/jcp.1041530317
Wang WS, Chen PM, Wang HS, Liang WY, Su Y (2006) Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 27(5):1113–1120. https://doi.org/10.1093/carcin/bgi351
Wang YQ, Miao ZH (2013) Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs 11(3):903–933. https://doi.org/10.3390/md11030903
Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J (1999) The generation of endostatin is mediated by elastase. Cancer Res 59(24):6052–6056
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–10086. https://doi.org/10.1074/jbc.271.17.10079
WHO fact sheet on cancer (2021). https://www.who.int/news-room/fact-sheets/detail/cancer
WHO fact sheet on cancer diagnosis (2018). https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
Winer A, Adams S, Mignatti P (2018) Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther 17(6):1147–1155. https://doi.org/10.1158/1535-7163.MCT-17-0646
Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA (2001) Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem 82(4):549–555. https://doi.org/10.1002/jcb.1181
Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154(5):1069–1079. https://doi.org/10.1083/jcb.200103111
Yadav PK, Gupta SK, Kumar S, Ghosh M, Yadav BS, Kumar D, Kumar A, Saini M, Kataria M (2021) MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice. Mol Cell Biochem 476(1):311–320. https://doi.org/10.1007/s11010-020-03908-2
Yadav PK, Gupta SK, Kumar S, Ghosh M, Yadav BS, Kumar D, Kumar A, Saini M, Kataria M (2020) IL-18 immunoadjuvanted xenogeneic canine MMP-7 DNA vaccine overcomes immune tolerance and suppresses the growth of murine mammary tumor. Int Immunopharmacol 82:106370. https://doi.org/10.1016/j.intimp.2020.106370
Yadav PK, Yadav BS, Panigrahi PN, Tripathi V, Chaturvedi N, Kataria M (2017) Molecular characterization and in-silico analysis of the tissue inhibitor of metalloproteinases-3 (TIMP-3) gene of canine mammary tumor. Comb Chem High Throughput Screen 20(6):539–546. https://doi.org/10.2174/1386207320666170217150741
Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X (2020) Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med 12(1):83. https://doi.org/10.1186/s13073-020-00780-z
Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P (2008) Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res 14(17):5503–5511. https://doi.org/10.1158/1078-0432.CCR-07-4041
Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16(3):307–323. https://doi.org/10.1101/gad.925702
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Yadav, P.K., Ghosh, M., Kataria, M. (2022). Matrix Metalloproteinases (MMPs) in Cancer Immunotherapy. In: Chakraborti, S. (eds) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-16-1247-3_182-1
Download citation
DOI: https://doi.org/10.1007/978-981-16-1247-3_182-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-1247-3
Online ISBN: 978-981-16-1247-3
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences